The relationship between the metabolic syndrome and energy-utilization deficit in the pathogenesis of obesity-induced osteoarthritis

Medical Hypotheses

Volumn 69, Issue 4, 2007, Pages 860-868

  Rojas Rodríguez, Jorge ^a   Escobar Linares, Luis E ^b   Garcia Carrasco, Mario ^a,c   Escárcega, Ricardo O ^c   Fuentes Alexandro, Salvador ^c   Zamora Ustaran, Alfonso ^d  

^a BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^b Hospital Universitario de Puebla   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE; GLITAZONE DERIVATIVE; GLUCOSE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 4; GLYCOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INSULIN RECEPTOR; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ENERGY EXPENDITURE; FATIGUE; GENE OVEREXPRESSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; MACROPHAGE; METABOLIC SYNDROME X; MUSCLE WEAKNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SKELETAL MUSCLE; TH1 CELL;

CYTOKINES; ENERGY METABOLISM; HUMANS; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; OBESITY; OSTEOARTHRITIS; TH1 CELLS;

EID: 34547912143     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.01.075     Document Type: Article

References (52)

1. Hochberg M.C. Epidemiology of osteoarthritis: current concepts and new insights. J Rheumatol Suppl. 271 (1991) 4-6
2. Felson D.T., Lawrence R.C., Dieppe P.A., et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 133 (2000) 1635-1646
3. Steven M.M. Prevalence of chronic arthritis in four geographical areas of the Scottish Highlands. Ann Rheum Dis 2 (1992) 186-194
4. Levy E., Ferme A., Perocheau D., and Bono I. Les couts socio-economiques de l'arthrose en France. Rev Rhum 6 pt2 (1993) 63S-67S
5. The International Diabetes Federation consensus worldwide definition of the metabolic syndrome; April 14th 2005.
6. Zavaroni I., Platti P.M., Monti L.D., Gasparini P., Barilli L.A., Massironi P., et al. Plasma nitric oxide concentrations are elevated in insulin-resistant healthy subjects. Metabolism 49 (2000) 959-961
7. Warram J.H., Martin B.C., Knolewski A.S., Soeldner J.S., and Kahn C.R. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 113 (1990) 909-915
8. Matthews D., Hosker J., Rudenski A., Naylor B., Treacher D., and Turner R. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
9. Lillioja S., Mott D.M., Howard B.V., et al. Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318 (1988) 1217-1225
10. Wright E.M., Turk E., Zabel B., Mundlos S., and Dyer J. Molecular genetics of intestinal glucose transport. J Clin Invest 88 (1991) 1435-1440
11. Shulman R.G., Bloch G., and Rothman D.L. In vivo regulation of muscle glycogen synthase and the control of glycogen synthesis. Proc Natl Acad Sci USA 92 (1995) 8535-8542
12. Shepherd PR, Kahn BB. Glucose transporters and insulin action. Implications for insulin resistance and diabetes mellitus. Review Articles Epstein FH (Ed). N Engl J Med 1999;341:248-257.
13. Cline G.W., Petersen K.F., Krssak M., Shen J., Hundal R.S., Trajanoski Z., et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341 (1999) 240-246
14. Shulman G.I. Cellular mechanisms of insulin resistance. J Clin Invest 106 (2000) 171-176
15. Hurley M.V. The role of muscular weakness in the pathogenesis of osteoarthritis. Rheumat Dis Clin North Am Book 1 2 (1999) 286-287
16. Dandona P., Aljada A., Chaundhuri A., Mohanty P., and Garg R. Metabolic syndrome a comprehensive perspective based on interactions between obesity, coma, diabetes and inflammation. Circulation 111 (2005) 1448-1454
17. Bullo M., Garcia-Lorda P., Peinado-Onsurbe J., Hernandez M., del Castillo D., Argiles J.M., et al. TNF-alpha expression of subcutaneous adipose tissue in obese and morbid obese females: relationship to adipocyte LPL activity and leptin synthesis. Int J Obes Relat Metab Disord 26 (2002) 652-658
18. Greenberg A.S., and McDaniel M.L. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 32 Suppl. 3 (2002) 24-34
19. Chu N.F., Spiegelman D., Hotamisligil G.S., Rifai N., Stampfer M., and Rimm E.B. Plasma insulin, leptin and soluble TNF receptor levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 157 (2001) 495-503
20. Fernandez-Real J.M., Pugeat M., Grasa M., Broch M., Vendrell J., Brun J., et al. Serum corticosteroid binding globulin concentration and insulin resistance syndrome: a population study. J Clin Endocrinol Metab 87 (2002) 4686-4690
21. Chalkley S.M., Hettiarachchi M., Chisholm D.J., and Kraegen E.W. Five-hour fatty acid elevation increases muscle lipids and impairs glycogen synthesis in the rat. Metabolism 47 (1998) 1121-1126
22. Hwang C.S., Loftus T.M., Mandrup S., and Lane M.D. Adipocyte differentiation and leptin expression. Annu Rev Cell Dev Biol 13 (1997) 231-259
23. Schwartz M., and Porte Jr. D. Diabetes, obesity, and the brain. Science 307 (2005) 375-379
24. Unger R.H., Zhou Y.T., and Orci L. Regulation of fatty acid homeostasis in cells; a novel role of leptin. Proc Natl Acad Sci USA 96 (1999) 2327-2332
25. McGarry J.D., and Dobbins R.L. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42 (1999) 128-138
26. Spiegelman B.M., and Flier J.S. Obesity and the regulation of energy balance. Cell 104 (2001) 531-543
27. Obici S., Wang J., Chowdury R., Feng Z., Siddhanta U., Morgan K., et al. Identification of a biochemical link between energy intake and energy expenditure. J Clin Invest 109 (2002) 1599-1605
28. Laybutt D.R., Schmitz-Peifer C., Saha A.K., Ruderman N.B., Biden T.G., and Kraegen E.W. Muscle lipid accumulation and protein kinase C, activation in the insulin-resistant chronically glucose-infused rat. Am J Physiol 277 (1999) E1070-E1076
29. Bell K.S., Schmitz-Peifer C., Lim-Fraser M., Biden T.J., Cooney G.J., and Kraegen E.W. Acute reversal of lipid-induced muscle insulin resistance is associated with rapid alteration in PKC-θ localization. Am J Physiol Endocrinol Metab 279 (2000) E1196-E1201
30. Itani S.I., Ruderman N.B., Schmieder F., and Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and I{κ}B-{α}. Diabetes 51 (2002) 2005-2011
31. Merrill G.F., Kurt E.J., Rasmussen B.B., and Winder W.W. Influence of malonyl-CoA and palmitate concentration on rate of palmitate oxidation in rat muscle. J Appl Physiol 85 (1998) 1909-1914
32. Sturmer T., Sun Y., Sauerland S., et al. Serum cholesterol and osteoarthritis: the baseline examination of the Ulm osteoarthritis study. J Rheumatol 25 (1998) 1827-1832
33. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Rev 20 (1999) 649
34. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P., et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-∝ in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 48 (1997) 1319-1327
35. Vidal-Puig A.J., Considine R.V., Jimenez-Linan M., Werman A., Pories W.J., Caro J.F., et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99 (1997) 2416-2422
36. Greene M.E., Blumberg B., McBride O.W., Yi H.F., Kronquist K., Kwan K., et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 4 (1995) 281-299
37. Kruszynska Y.T., Mukherjee R., Jow L., Dana S., Paterniti Jr. J.R., and Olefsky J.M. Skeletal muscle peroxisome proliferator-activated receptor γ expression in obesity and non-insulin-dependent diabetes mellitus. J Clin Invest 101 (1998) 543-548
38. Zhang B., Berger J., Hu E., Szalkowski D., White-Carrington S., Spiegelman B.M., et al. Negative regulation of peroxisome proliferator activated receptor-γ gene expression contributes to antiadipogenic effects of tumor necrosis factor-α. Mol Endocrinol 10 (1996) 1457-1466
39. Palmer R.M., Ferrige A.G., and Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 (1987) 524-526
40. Garg U.C., and Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83 (1989) 1774-1777
41. Ignarro L.J. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 65 (1989) 1-21
42. Radomski M.W., Vallance P., Whitley G., Foxwell N., and Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res 27 (1993) 1380-1382
43. Tack C.J., Lutterman J.A., Vervoort G., Thien T., and Smits P. Activation of the sodium-potassium pump contributes to insulin-induced vasodilation in humans. Hypertension 28 (1996) 426-432
44. Shears II L.L., Nobuyoshi K., Tzeng E., Billiar T.R., Watkins S.C., Kovesdi I., et al. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest 100 (1997) 2035-2042
45. Singh G., Miller J.D., Lee F.H., Pettitt D., and Russell M.W. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data form the third National Health and Nutrition Examination Survey. Am J Manag Care 8 Suppl. 15 (2002) S383-S391
46. Conaghan P.G., Vanharanta H., and Dieppe P.A. Is progressive Osteoarthritis an atheromatous vascular disease?. Ann Rheum Dis 64 (2005) 1539-1541
47. Alexander C.J. Heberden's and Bouchard's nodes: hypothesis. Ann Rheum Dis 58 (1999) 675-678
48. Peraldi P., Xu M., and Spiegelman B.M. Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling. J Clin Invest 100 (1997) 1863-1869
49. Maier V.H., Melvin D.R., Lister C.A., Chapman H., Gould G.W., and Murphy G.J. v-and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects over expression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of zucker diabetic fatty rats. Diabetes 49 (2000) 618-625
50. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 106 (2000) 189-197
51. Wieseneberg I., Chiesi M., Missbach M., Spanka C., Pignat W., and Carlberg C. Specific activation of the nuclear receptors PPARγ and RORA by the antiabetic thiazolidinedione BRL 49653 and the antiarthritic thiazolidinedione derivative CGP 52608. Mol Pharmacol 53 (1998) 1131-1138
52. Jason K.K., Fillmore J.J., et al. Differential Effects of Rosiglitazone on Skeletal Muscle and Liver Insulin Resistance in A-ZIP/F-1 Fatless Mice. Diabetes 52 (2003) 1311-1318